Overview
Actively managed equity portfolio investing worldwide in companies from the health transformation sector.
Efficient means of exploiting the potential of companies operating in the health Transformation area.
Specialised sector analysts seek out the attractive stocks in the Health Transformation area.
Investment decisions are based on a disciplined investment philosophy and fundamental research.
This fund promotes environmental, social and corporate governance characteristics. The research and portfolio construction processes incorporate ESG risk integration and screening and comply with UBS SA国际传谋 Sustainability exclusion policy. For more information on Sustainability at UBS, please refer to www.ubs.com/am-si-commitment.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
The fund is pairing CIO identified investment themes with the stock selection and portfolio construction expertise of UBS SA国际传谋.
The fund taps into the knowledge of proven sector specialists.
UBS’s proprietary fundamental valuation approach allows consistent identification of the most attractive global health transformation companies.
Investors benefit from a global investment platform of UBS SA国际传谋.
Risks
Features
| Product category |
UBS Equity Funds UBS Sector Funds |
| Product domicile |
Luxembourg
|
| Portfolio management |
UBS SA国际传谋 (Americas) LLC, New York
|
| Fund management |
UBS SA国际传谋 (Europe) S.A., Luxembourg
|
| Custodian bank |
UBS Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
UBS AG, Stockholm
|
| Day of inception |
May 27, 1998
|
| Currency of account |
USD
|
| Close of financial year |
November 30
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
1.79% p.a.
|
| Management fee |
1.37% p.a.
|
| Total expense ratio (TER) |
1.78% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI World Health Care (net div. reinv.)
|
| ISIN |
LU0085953304
|
| Bloomberg Ticker |
UBSEHLI LX
|
| Telekurs Id |
EQHC
|
Performance and Prices
Percentage growth
as of April 23, 2026| USD(%) | EUR(%) | |
| YTD | ||
| 1M | ||
| 3M | ||
| 6M | ||
| 1Y | 19.98 | 16.29 |
| 2Y | ||
| 3Y | 26.52 | 18.55 |
| 5Y | 29.30 | 33.03 |
| ø p.a.5Y | 5.27 | 5.87 |
Current data
| Net asset value | 23.04.2026 | USD 501.81 |
| High - last 12 months | 27.02.2026 | USD 530.52 |
| Low - last 12 months | 14.05.2025 | USD 404.91 |
| Assets of the unit class in mn | 23.04.2026 | USD 106.75 |
| Total product assets in mn | 23.04.2026 | USD 266.73 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.03.2026 | 14.34% | 14.13% |
| Sharpe Ratio | 31.03.2026 | 0.09 | 0.13 |
| Risk Free Rate | 31.03.2026 | 4.55% | 3.51% |
Structures
By the 10 largest equity positions (in %, as of March 31, 2026)
|
|
|
| Eli Lilly & Co | 9.11 |
| AstraZeneca PLC | 8.83 |
| UnitedHealth Group Inc | 5.17 |
| Sandoz Group AG | 4.87 |
| Novartis AG | 4.84 |
| Koninklijke Philips NV | 4.81 |
| Alcon AG | 4.74 |
| Bristol-Myers Squibb Co | 4.18 |
| Intuitive Surgical Inc | 4.12 |
| Chugai Pharmaceutical Co Ltd | 4.03 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
||
| Prospectus |
|
||
| Key Information Document |
|
||
| Past performance |
|
||
| Previous performance scenario |
|
||
| Statutes / Management regulations |
|
||
| ESG Disclosure |
|
|
|
| SFDR Pre-Contractual Annex |
|
|
Document type
|
Document Language
|
| Annual report |
|
| SFDR Periodic Report Annex |
|
| Semi-annual report |
|